T 0764/06 (Crystalline form of atorvastatin/WARNER-LAMBERT COMPANY LLC) of 25.02.2009
- European Case Law Identifier
- ECLI:EP:BA:2009:T076406.20090225
- Date of decision
- 25 February 2009
- Case number
- T 0764/06
- Online on
- 14 July 2009
- Petition for review of
- -
- Application number
- 96924368.2
- IPC class
- C07D 207/34
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Crystalline R-(R*,R*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
- Applicant name
- Warner-Lambert Company LLC
- Opponent name
- Teva Pharmaceutical Industries Ltd.
LEK Pharmaceutical and Chemical Company d.d. - Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 114(2) 1973European Patent Convention Art 113(1) 1973European Patent Convention Art 100(c) 1973Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)European Patent Convention R 55(c) 1973European Patent Convention R 76(c)
- Keywords
- Admissibility of allegedly new ground of opposition (yes)
Added matter (yes) - Omission of an essential feature
Late-filed request (not admitted) - Catchword
- -
ORDER
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.